Fred Hassan filed an initial statement of beneficial ownership with the SEC on November 4, 2026, disclosing his status as a newly appointed director of Recursion Pharmaceuticals, Inc. as of October 31, 2026.

Key Highlights

  • Reporting person: Fred Hassan, identified as a Director of Recursion Pharmaceuticals, Inc.
  • Event date: The date of the event requiring the statement is October 31, 2026.
  • No securities held: The filing states "No securities are beneficially owned" in both Table I (non-derivative) and Table II (derivative) sections.
  • Filing date: The form was signed and filed on November 4, 2026, by Kyle Nelson as attorney-in-fact.
  • Individual filing: The form was filed by one reporting person acting alone.

Recursion Pharmaceuticals Director Fred Hassan Reports No Initial Securities Holdings

Fred Hassan submitted a Form 3 initial statement of beneficial ownership to the U.S. Securities and Exchange Commission on November 4, 2026, in connection with his becoming a director of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX). According to the filing, the event requiring the statement occurred on October 31, 2026.

The filing discloses that Hassan holds no securities of the issuer at the time of the initial statement. Both Table I, covering non-derivative securities, and Table II, covering derivative securities such as puts, calls, warrants, options, and convertible securities, contain no entries. The filing includes the remark: "No securities are beneficially owned."

The form was signed on November 4, 2026, by Kyle Nelson as attorney-in-fact for the reporting person. Hassan's address is listed as 41 S. Rio Grande St., Salt Lake City, Utah 84101. The filing indicates it was submitted by one reporting person and checks only the "Director" box in the relationship-to-issuer section, with no officer title or other relationship indicated.

What Was Disclosed

Fred Hassan filed a Form 3 as a newly appointed director of Recursion Pharmaceuticals, Inc., with an event date of October 31, 2026. The filing reports no direct or indirect beneficial ownership of any securities of the issuer.